Phase 2
Completed N=207
Testing Mestinon and Exercise in Fibromyalgia
Source: ClinicalTrials.gov NCT00535587 ↗Enrolled (actual)
207
Serious AEs
0.0%
Results posted
Apr 2011
Primary outcomePrimary: Levels of Growth Hormone Post Exercise — 4.95; 1.41 ng/ml — p=<0.02
Summary
The purpose of this trial was to test the combined and independent effects of 6 months of exercise and Mestinon in people with fibromyalgia. Specifically, we wanted to determine if Mestinon helped people with fibromyalgia have an easier time exercising and if their symptoms improved by the end of the trial.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Levels of Growth Hormone Post Exercise |
4.95; 1.41 | <0.02 sig |
| SECONDARY Improvement of Fibromyalgia Symptoms |
— | — |
Eligibility Criteria
Inclusion Criteria
- Have Fibromyalgia
Exclusion Criteria
- Subjects will be excluded if they have a history of rheumatic disease or other disorder that may compromise ability to safely complete study protocol, be pregnant, nursing, or currently involved in unresolved litigation.
Data sourced from ClinicalTrials.gov (NCT00535587). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.